Exclusive: After cutting most staff, Casma eyes path to clinic with its first autophagy-boosting drug

Ryan Cross

Senior Science Correspondent

Casma Therapeutics is unveiling its first preclinical data suggesting that a novel drug can enhance the ability of brain cells to clear out molecular garbage …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Exclusive: After cutting most staff, Casma eyes path to clinic with its first autophagy-boosting drug

Ryan Cross

Senior Science Correspondent

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

MIT scientists’ AI model one-ups AlphaFold 3, takes on ‘fundamental issue’ in drug R&D

Updated: Omada Health rose 21% in its public market debut

Is there still hope for Summit's cancer drug buried in the data?

EMA considers serious eye condition a ‘very rare’ side effect of semaglutide

GSK taps Sanofi vet to lead vaccine R&D; Bristol Myers names head of corporate affairs

Cytiva and EurekaBio form strategic partnership to advance lentiviral vector manufacturing for cell and gene therapy ...

Ex­clu­sive: Af­ter cut­ting most staff, Cas­ma eyes path to clin­ic with its first au­tophagy-boost­ing drug

Senior Science Correspondent

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Exclusive: After cutting most staff, Casma eyes path to clinic with its first autophagy-boosting drug